Bracco forms unit to develop therapeutic radiopharmaceuticals

By staff writers

March 2, 2022 -- Bracco Imaging has launched a new subsidiary called Blue Earth Therapeutics to advance the development of radiopharmaceutical technology.

Initially, Blue Earth Therapeutics is building a portfolio of precision-targeted radiopharmaceuticals focused on prostate cancer. In the future, it will expand to additional diseases in oncology.

Also, the subsidiary has exclusive rights to therapeutic applications of radiohybrid prostate-specific membrane antigen radiopharmaceutical technology. David Gauden, PhD, is CEO of Blue Earth Therapeutics.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking